Table VI 
Engraftment After Autologous BM and/or PBSCs 
SC *Day to Day to Day to Day to 
Source Regimen Pts. >100 >500 >1,000 >20,000 
PBSC 
alone 
Bu/Cy 
4 
11.8 
(11-13) 
12.8 
(12-14) 
14 
(13-15) 
11 
(9-13) 
PBSC+B 
M+G- 
CSF 
BU/Cy 
Cy/TBI 
other 
Total 
4 
2 
3 
2 
9.2 
(8-12) 
10.8 
(9-14) 
11.5 
(9-15) 
15 
(11-30) 
BM alone 
Bu/Cy 
19 
12.5 
(10-16) 
19.9 
(12-51+) 
25.5 
(13-62+) 
41.5 
(9-85+) 
BM+GM 
CSF 
Cy/TBI 
22 
11.9 
(9-18) 
17.4 
(11-40) 
20.8 
(12-42+) 
22.1 
(10-101) 
* = mean () = range, (+) = patients not achieving given levels of neutrophils or platelets. 
4. Objectives.. 
A. The primary objective is to determine if prompt and enduring engraftment can be 
achieved with the use of G-CSF mobilized PBSC’s in identical twins with malignant 
disease. 
B. Secondary objectives include: 
(1) Determination of the contribution of genetically marked PBSC’s to long-term 
engraftment as outlined in protocol 691. 
(2) Comparison of the tempo of engraftment and transfusion requirements with 
historical control patients receiving marrow alone, marrow followed by growth 
factors or marrow plus PBSC’s. 
(3) Comparison of the relative morbidity and expense of using PBSC’s versus 
marrow. 
5. Patient and Donor Selection. 
A. Inclusions: 
(1) Any patient age 18 or greater receiving an identical twin transplant for 
malignancy whose donor is suitable and willing to undergo multiple apheresis 
procedures. 
B. Exclusions: 
(1) Inadequate documentation that donor and recipient are syngeneic. Twin studies 
must include ABO typing, HLA typing and DNA fingerprinting studies (Dr Paul 
Martin). The latter should be performed prior to arrival in Seattle due to the 
length of time required to perform the test. The documentation of twinning is 
extremely important due to the unavoidable infusion of peripheral blood 
lymphocytes with PBSCs that could cause graft-versus-host-disease. If there are 
any doubts such patients are excluded from this study. 
(2) Recipients who are CMV negative and have a CMV positive donor. 
Recombinant DNA Research, Volume 16 
[365] 
